Remove clinical flu
article thumbnail

Vaxess' flu vaccine patch passes early clinical test, clearing path for further development

Fierce Pharma

Vaxess' flu vaccine patch passes early clinical test, clearing path for further development. Tue, 12/20/2022 - 04:57.

216
216
article thumbnail

First adaptive clinical trial for flu

European Pharmaceutical Review

million, UK-wide adaptive platform trial (APT) has been launched to find effective treatments for people hospitalised with severe flu for the first time, testing multiple options simultaneously in thousands of people then modifying treatments quickly. National Institute for Health and Care Research (NIHR)’s Clinical Research Network.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

mRNA can deliver universal flu vaccine, say US researchers

pharmaphorum

While the shot is still in preclinical development, if it works in human trials it could raise the prospect of eventually sidestepping the annual scramble to guess the most likely strains to be circulating in the following flu season, and protect against future flu pandemics.

article thumbnail

Next-gen Moderna COVID-19 vaccine shows promise

European Pharmaceutical Review

. “mRNA-1283 is a critical component of our combination vaccine against flu and COVID-19, mRNA-1083, and this milestone gives us confidence in our ability to bring this much needed vaccine to market.” 5 and original virus strains of SARS-CoV-2, compared to Moderna’s Spikevax vaccine.

Safety 93
article thumbnail

FLU-SV-mRNA by Curevac for Influenza A Virus, H1N1 Subtype Infections: Likelihood of Approval

Pharmaceutical Technology

FLU-SV-mRNA is under clinical development by Curevac and currently in Phase I for Influenza A Virus, H1N1 Subtype Infections.

40
article thumbnail

FLU-SV-mRNA by Curevac for Influenza A Virus, H1N1 Subtype Infections: Likelihood of Approval

Pharmaceutical Technology

FLU-SV-mRNA is under clinical development by Curevac and currently in Phase I for Influenza A Virus, H1N1 Subtype Infections.

40
article thumbnail

UK, Moderna formalise 10-year vaccines alliance

pharmaphorum

It also said the alliance will see Moderna invest in R&D in the UK over the next 10 years, including running a number of clinical trials and providing grant funding to UK universities, while the manufacturing facility will create more than 150 highly skilled jobs. The first vaccines are due to be produced at the new facility in 2025.